Day: March 5, 2025

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

Written by Customer Service on March 5, 2025. Posted in Mergers And Acquisitions.

-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz’s pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both companies and is expected to close in the second quarter of 2025. Chimerix’s lead clinical asset is dordaviprone, a novel first-in-class small molecule treatment...

KP Tissue Releases Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

Record revenue surpasses $2-billion mark in 2024 combined with strong Adjusted EBITDA in all four quarters MISSISSAUGA, Ontario, March 05, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2024 and full year 2024 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.5% interest in Kruger Products. Kruger Products Q4 2024 Business and Financial HighlightsRevenue was $539.6 million in Q4 2024 compared to $482.3 million...

NuVista Energy Ltd. Announces Record Year End 2024 Reserves, Financial and Operating Results

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, March 05, 2025 (GLOBE NEWSWIRE) — NuVista Energy Ltd. (“NuVista” or the “Company“) (TSX: NVA) is pleased to announce record-setting reserves and strong financial and operating results for the three months and year ended December 31, 2024. The repeatable, predictable and profitable nature of our assets have once again underpinned significant growth in our reserves. Continued success in the Lower Montney and sanctioning of our Gold Creek area expansion have set the stage for continued growth toward 125,000 Boe/d. We are entering 2025 in a strong financial position with operational momentum and a commitment to shareholder returns. We are pleased to reaffirm our annual capital and production guidance for the year. Operational and Financial Highlights During the fourth quarter and year ended...

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

– Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25– Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025– Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial– EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25– Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2025 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth...

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and provided a business...

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

– Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash and investments on December 31, 2024, providing cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – WATERTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2024, and highlighted recent corporate developments. “We are off to a strong start in 2025, as we...

Broadwind Announces Fourth Quarter and Full-Year 2024 Results

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

CICERO, Ill., March 05, 2025 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the fourth quarter and full-year 2024. FOURTH QUARTER 2024 RESULTSTotal revenue of $33.6 million Net loss of ($0.9) million, or ($0.04) per share Total non-GAAP adjusted EBITDA of $2.1 million, or 6.4% of total revenue Ratio of net debt to trailing twelve-month non-GAAP adjusted EBITDA of 0.6x as of December 31, 2024FULL-YEAR 2024 RESULTSTotal revenue of $143.1 million Net income of $1.2 million, or $0.05 per share Total non-GAAP adjusted EBITDA of $13.3 million, or 9.3% of total revenueBroadwind reported a net loss of ($0.9) million, or ($0.04) per share in the fourth quarter 2024, compared to net income...

Hydrofarm Holdings Group Announces Fourth Quarter and Full Year 2024 Results

Written by Customer Service on March 5, 2025. Posted in Earnings Releases And Operating Results.

SHOEMAKERSVILLE, Pa., March 05, 2025 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter Highlights vs. Prior Year Period:Net sales decreased to $37.3 million compared to $47.2 million. Gross Profit and Adjusted Gross Profit(1) of $1.8 million and $3.6 million. Gross Profit Margin decreased to 4.9% of net sales compared to 17.9%. Adjusted Gross Profit Margin(1) decreased to 9.6% of net sales compared to 24.3%. SG&A expense and Adjusted SG&A(1) expense decreased by (14.7)% and (9.8)%, respectively. Net loss increased to $17.5 million...

Ollie’s Bargain Outlet Announces Fourth Quarter and Full-Year Fiscal 2024 Earnings Release Date and Conference Call Information

Written by Customer Service on March 5, 2025. Posted in Public Companies.

HARRISBURG, Pa., March 05, 2025 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today announced it will release its fourth quarter and full-year fiscal 2024 financial results before the market opens on Wednesday, March 19, 2025. At 8:30 a.m. Eastern Time on the same day, Eric van der Valk, President and Chief Executive Officer, and Robert Helm, Executive Vice President and Chief Financial Officer, will host the call with the investment community to discuss the financial results and answer questions. To access the live conference call, please pre-register here. Registrants will receive a confirmation with dial-in instructions. Interested parties can also listen to a live webcast or replay of the conference call by logging on to the Investor Relations section on the Company’s website at https://investors.ollies.com. About...

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Written by Customer Service on March 5, 2025. Posted in Public Companies.

LONDON, March 05, 2025 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. A live audio webcast of the fireside chat can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company’s website for two weeks following the live event. About Mereo BioPharmaMereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease...

Day: March 5, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals